$BZYR
BURZYNSKI RESEARCH INSTITUTE INC

2023 Q1 Form 10-Q Financial Statement

#000155837023000269 Filed on January 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $43.45K $44.99K
YoY Change -0.89% -11.19%
% of Gross Profit
Research & Development $172.6K $207.7K
YoY Change 35.82% -3.02%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $216.0K $252.6K
YoY Change 26.4% -4.58%
Operating Profit -$252.6K
YoY Change -4.58%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$216.0K -$252.6K
YoY Change 26.4% -4.58%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$216.0K -$252.6K
YoY Change 26.4% -4.58%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 131.4M 131.4M
Diluted Shares Outstanding 131.4M

Balance Sheet

Concept 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $930.00 $1.690K
YoY Change -72.49% -70.71%
Cash & Equivalents $934.00 $1.692K
Short-Term Investments
Other Short-Term Assets $1.000K $100.00
YoY Change -21.88% -89.69%
Inventory
Prepaid Expenses $1.000K $100.00
Receivables
Other Receivables
Total Short-Term Assets $1.934K $1.792K
YoY Change -58.51% -73.41%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.934K $1.792K
Total Long-Term Assets $0.00 $0.00
Total Assets $1.934K $1.792K
YoY Change -58.51% -73.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.57K $16.65K
YoY Change 1098.7%
Accrued Expenses $3.091K $11.77K
YoY Change -10.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.66K $28.42K
YoY Change 352.6% 1944.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $15.66K $28.42K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $15.66K $28.42K
YoY Change 353.29% 1946.08%
SHAREHOLDERS EQUITY
Retained Earnings -$126.8M -$126.5M
YoY Change 0.73% 0.69%
Common Stock $126.7M $126.5M
YoY Change 0.72% 0.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.73K -$26.63K
YoY Change
Total Liabilities & Shareholders Equity $1.934K $1.792K
YoY Change -58.51% -73.41%

Cashflow Statement

Concept 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$216.0K -$252.6K
YoY Change 26.4% -4.58%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$73.28K -$47.59K
YoY Change 26.13% -49.99%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 72.52K 48.02K
YoY Change 30.15% -51.99%
NET CHANGE
Cash From Operating Activities -73.28K -47.59K
Cash From Investing Activities
Cash From Financing Activities 72.52K 48.02K
Net Change In Cash -760.0 430.0
YoY Change -68.07% -91.15%
FREE CASH FLOW
Cash From Operating Activities -$73.28K -$47.59K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
dei Entity Registrant Name
EntityRegistrantName
BURZYNSKI RESEARCH INSTITUTE INC
dei Entity Central Index Key
EntityCentralIndexKey
0000724445
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
dei Security Exchange Name
SecurityExchangeName
NONE
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131448444
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
131449
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131448444
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131448444
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
131449
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
126380700
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
125708240
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126538777
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125838483
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-26628
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1206
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1792
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4661
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
dei Document Period End Date
DocumentPeriodEndDate
2022-11-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-23425
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0136810
dei Entity Address Address Line1
EntityAddressAddressLine1
9432 Katy Freeway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77055
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
335-5697
dei Security12b Title
Security12bTitle
None
dei Trading Symbol
TradingSymbol
BZYR
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131448444
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1692
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3382
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
100
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1279
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1792
CY2022Q1 us-gaap Assets Current
AssetsCurrent
4661
CY2022Q4 us-gaap Assets
Assets
1792
CY2022Q1 us-gaap Assets
Assets
4661
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16650
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11770
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3455
CY2022Q4 us-gaap Liabilities
Liabilities
28420
CY2022Q1 us-gaap Liabilities
Liabilities
3455
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131448444
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
207651
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
214112
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44988
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50664
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
252639
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
264776
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-252639
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-264776
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-252639
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-264776
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-252639
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-264776
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
545960
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
632475
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
154334
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
173302
us-gaap Operating Expenses
OperatingExpenses
700294
us-gaap Operating Expenses
OperatingExpenses
805777
us-gaap Operating Income Loss
OperatingIncomeLoss
-700294
us-gaap Operating Income Loss
OperatingIncomeLoss
-805777
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-700294
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-805777
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-700294
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-805777
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1206
CY2022Q2 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
40517
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
151334
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-231737
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-38680
CY2022Q3 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
86017
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
154943
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-215918
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-13638
CY2022Q4 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
48017
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
191632
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-252639
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-26628
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-45843
CY2021Q2 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
84967
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
215926
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-316283
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-61233
CY2021Q3 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
87717
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
170403
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-224718
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-27831
CY2021Q4 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
100017
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
197940
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-264776
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5350
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-700294
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-805777
bzyr Clinical Trial Expenses Paid
ClinicalTrialExpensesPaid
497909
bzyr Clinical Trial Expenses Paid
ClinicalTrialExpensesPaid
584270
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1179
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
80
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
16650
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-31123
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8315
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-14287
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-176241
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-266997
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
174551
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
272701
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
174551
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
272701
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1690
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5704
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3382
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1692
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5766
CY2022Q4 bzyr Ownership Interest Percentage Held By Company President And Chairman Of Board
OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard
0.810
bzyr Number Of Patents Owned
NumberOfPatentsOwned
1
bzyr Number Of Antineoplaston Drugs That Received Fda Approval
NumberOfAntineoplastonDrugsThatReceivedFDAApproval
0
bzyr Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans
1
CY2022Q4 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2728
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q4 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-53054
CY2021Q4 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-55603
CY2022Q4 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
53054
CY2021Q4 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
55603
CY2022Q4 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
2728
CY2021Q4 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-6968
CY2021Q4 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6968
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-147062
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-169213
us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
147062
us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
169213
us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
5845
us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-10751
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-5845
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
10751
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
164547
us-gaap Revenues
Revenues
0
bzyr Percentage Of Future Taxable Income Net Operating Loss Carryforwards
PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards
0.80
bzyr Percentage On Net Operating Loss Carryforwards Limit Of Taxable Income Under Coronavirus Aid Relief And Economic Security Act
PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct
0.80
bzyr Percentage Of Future Taxable Income Net Operating Loss Carryforwards
PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards
0.80
bzyr Net Operating Loss Carry Forward Indefinitely
NetOperatingLossCarryForwardIndefinitely
106782

Files In Submission

Name View Source Status
0001558370-23-000269-index-headers.html Edgar Link pending
0001558370-23-000269-index.html Edgar Link pending
0001558370-23-000269.txt Edgar Link pending
0001558370-23-000269-xbrl.zip Edgar Link pending
bzyr-20221130.xsd Edgar Link pending
bzyr-20221130x10q.htm Edgar Link pending
bzyr-20221130xex31d1.htm Edgar Link pending
bzyr-20221130xex31d2.htm Edgar Link pending
bzyr-20221130xex32d1.htm Edgar Link pending
bzyr-20221130xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bzyr-20221130_cal.xml Edgar Link unprocessable
bzyr-20221130_def.xml Edgar Link unprocessable
bzyr-20221130_pre.xml Edgar Link unprocessable
bzyr-20221130_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bzyr-20221130x10q_htm.xml Edgar Link completed